Evidence map›Paper›PMID 34579894›Full record

ArticleMaterials science & engineering. C, Materials for biological applications2021

Development of drug loaded cardiovascular prosthesis for thrombosis prevention using 3D printing.

Juan Domínguez-Robles, Tingjun Shen, Victoria A Cornelius, Francesca Corduas, Elena Mancuso, Ryan F Donnelly, Andriana Margariti, Dimitrios A Lamprou, Eneko Larrañeta

Open access · hybridAbstract read
In one paragraph

Article in Materials science & engineering. C, Materials for biological applications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Juan Domínguez-RoblesSchool of Pharmacy, Queen's University Belfast, Lisburn Road 97, Belfast BT9 7BL, UK.
Tingjun ShenSchool of Pharmacy, Queen's University Belfast, Lisburn Road 97, Belfast BT9 7BL, UK.
Victoria A CorneliusWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast BT9 7BL, UK.
Francesca CorduasNanotechnology and Integrated Bio-Engineering Centre (NIBEC), Ulster University, Jordanstown Campus, Newtownabbey BT37 0QB, UK.
Elena MancusoNanotechnology and Integrated Bio-Engineering Centre (NIBEC), Ulster University, Jordanstown Campus, Newtownabbey BT37 0QB, UK.
Ryan F DonnellySchool of Pharmacy, Queen's University Belfast, Lisburn Road 97, Belfast BT9 7BL, UK.
Andriana MargaritiWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast BT9 7BL, UK.
Dimitrios A LamprouSchool of Pharmacy, Queen's University Belfast, Lisburn Road 97, Belfast BT9 7BL, UK.
Eneko LarrañetaSchool of Pharmacy, Queen's University Belfast, Lisburn Road 97, Belfast BT9 7BL, UK. Electronic address: e.larraneta@qub.ac.uk.
Queen's University Belfast · GBUniversity of Ulster · GB

Funding

British Heart Foundation FS/15/23/31435British Heart Foundation PG/16/8/31985British Heart Foundation PG/18/29/33731Wellcome Trust
6 · The paper itself

Abstract

Cardiovascular disease (CVD) is a general term for conditions which are the leading cause of death in the world. Quick restoration of tissue perfusion is a key factor to combat these diseases and improve the quality and duration of patients' life. Revascularization techniques include angioplasty, placement of a stent, or surgical bypass grafting. For the latter technique, autologous vessels remain the best clinical option; however, many patients lack suitable autogenous due to previous operations and they are often unsuitable. Therefore, synthetic vascular grafts providing antithrombosis, neointimal hyperplasia inhibition and fast endothelialization are still needed. To address these limitations, 3D printed dipyridamole (DIP) loaded biodegradable vascular grafts were developed. Polycaprolactone (PCL) and DIP were successfully mixed without solvents and then vascular grafts were 3D printed. A mixture of high and low molecular weight PCL was used to better ensure the integration of DIP, which would offer the biological functions required above. Moreover, 3D printing technology provides the ability to fabricate structures of precise geometries from a 3D model, enabling to customize the vascular grafts' shape or size. The produced vascular grafts were fully characterized through multiple techniques and the last step was to evaluate their drug release, antiplatelet effect and cytocompatibility. The results suggested that DIP was properly mixed and integrated within the PCL matrix. Moreover, these materials can provide a sustained and linear drug release without any obvious burst release, or any faster initial release rates for 30 days. Compared to PCL alone, a clear reduced platelet deposition in all the DIP-loaded vascular grafts was evidenced. The hemolysis percentage of both materials PCL alone and PCL containing 20% DIP were lower than 4%. Moreover, PCL and 20% DIP loaded grafts were able to provide a supportive environment for cellular attachment, viability, and growth.

Indexed as

Pharmaceutical PreparationsThrombosisAnticoagulantsBlood Vessel ProsthesisHumansPolyestersPrinting, Three-DimensionalAnticoagulantsPharmaceutical PreparationsPolyesters3D printingAntithrombotic effectBiodegradable vascular graftsDipyridamolePolycaprolactone

Identifiers

PMID34579894
PMCPMC8505756
OpenAlexW3193339239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.